Edit
Enterprise Therapeutics
http://www.enterprisetherapeutics.com/Last activity: 30.01.2026
Active
Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.
In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlying mechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
The leadership team has significant expertise in drug discovery, drug development, respiratory biology and ion channel pharmacology. The company benefits from a close working relationship with the School of Life Sciences at the University of Sussex.
Location: United Kingdom, England, Brighton
Employees: 1-10
Total raised: $85.47M
Founded date: 2014
Investors 2
| Date | Name | Website |
| 12.01.2023 | Forbion | forbion.co... |
| - | Epidarex C... | epidarex.c... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 30.01.2024 | Series B | $32.96M | - |
| 03.05.2018 | Series B | $41.3M | - |
| 13.11.2016 | - | $5.02M | - |
| 20.05.2015 | Series A | $3.73M | - |
| 16.02.2015 | Series A | $2.46M | - |
Mentions in press and media 17
| Date | Title | Description |
| 03.02.2026 | UK Government Embraces Activist Investment, Fuels "Picking Winners" Debate | The UK government champions an activist investment strategy. Business Secretary Peter Kyle explicitly backs "picking winners." He defends state intervention through entities like the British Business Bank. Kyle views calculated ri... |
| 30.01.2026 | Epidarex Capital Secures $145+ Million First Close For Fund IV To Invest In Life Science Startups | Epidarex Capital announced it has reached a first close of Epidarex Capital IV, LP, with more than $145 million in commitments, as the transatlantic life sciences venture firm looks to expand its company creation and early-stage investing a... |
| 30.01.2024 | Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing | Round led by new investor Panakes, with participation from all existing investors Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansion Dr Ro... |
| 30.01.2024 | Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing | • Round led by new investor Panakes, with participation from all existing investors • Funding will support Phase 2a clinical proof of concept trial in cystic fibrosis for a novel first in class ENaC blocker (ETD001) and pipeline expansion •... |
| 30.01.2024 | Enterprise Therapeutics Closes £26M Series B Follow-on Financing | Enterprise Therapeutics, a Brighton, UK-based biopharmaceutical company dedicated to the discovery and development of novel therapies for respiratory disease, raised £26M in Series B follow-on funding. The round was led by Panakes Partners.... |
| 14.06.2021 | Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001 | Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001 14-06-2021 Brighton, UK, 14 June 2021: Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and developmen... |
| 13.04.2018 | Term Sheet — Friday April 13 | IPO LAND Happy Friday, Term Sheet readers. Lucinda again filling in for Polina. Feel free to ping me at Lucinda.shen@fortune.com. Paid Content You can't secure what you can't see From ExtraHop Zuora popped 43% to $20 in its first day of tra... |
| 12.04.2018 | Enterprise Therapeutics Raises £29M in Funding | Enterprise Therapeutics Ltd, a Brighton, England, UK-based biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, closed an oversubscribed £29m ($41m) Series B fundi... |
| 12.04.2018 | Epidarex-backed Enterprise Therapeutics Raises £29M ($41M) Funding | Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has closed an oversubscribed £29 million ($41 million U... |
| 05.04.2017 | Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust | Enterprise Therapeutics Ltd, a Brighton, England, UK-based drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, raised funding from the Cystic Fibrosis Trust. The fun... |
Show more